BWI-CTU Researchers Elected to ACTG Network Committees

Published Date:

11/30/2016

November 29, 2016—The ACTG Network announced today the results of elections for the network's laboratory, leadership, science, and resource committees. Congratulations to the following BWI-CTU researchers, who were elected to serve for the term of December 1, 2016 – November 30, 2017:

  • Christine Durand, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
     
  • David Hardy, Whitman-Walker Clincial Trials Site (Washington)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Ya-Chi Ho, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Charles Flexner, Johns Hopkins Clincial Trials Site (Baltimore)
    Non-voting Member, Antiretroviral Therapy Strategies Subcommittee.  
        
  • Vidya Mave, Byramjee Jeejeebhoy Clincial Trials Site (India)
    Investigator, Tuberculosis Transformative Science Group.  
       
  • Eric Nuermberger, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, Tuberculosis Transformative Science Group.  
        
  • Ilene Wiggins, Johns Hopkins Clincial Trials Site (Baltimore)
    Chair, Site Management & Clinical Care Committee

Clinical Trials

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More